Bausch & Lomb's revenue for the
three
months ended in Sep. 2024 was €1,078 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €4,294 Mil.
Bausch & Lomb's Revenue per Share for the
three
months ended in Sep. 2024 was €3.05.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €12.20.
During the past 12 months, the average Revenue per Share Growth Rate of Bausch & Lomb was 17.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 8.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Bausch & Lomb's highest 3-Year average Revenue per Share Growth Rate was 8.30% per year. The lowest was -0.70% per year. And the median was 0.90% per year.
Bausch & Lomb Revenue Historical Data
The historical data trend for Bausch & Lomb's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb's Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Revenue distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Revenue falls into.
Bausch & Lomb Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €4,294 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (STU:S2L) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Bausch & Lomb Revenue Related Terms
Thank you for viewing the detailed overview of Bausch & Lomb's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:S2L has been successfully added to your 